Attached is a copy of a press release being issued by us regarding the filing of a new patent application more fully described in Item 8.01 below. a copy of which is attached as Exhibit 99.1 and is hereby incorporated.
Item 8.01 Other Events
On May 22, 2020, we filed a patent application in the United States for a new treatment for Coronavirus infections, including COVID-19. Our patent application covers composition subject matter pertaining to small molecules for inhibition of the main Coronavirus protease (Mpro), an enzyme that is essential for viral replication. The small molecules covered by the patent application were computer modelled and designed by Dr. Steve N. Slilaty, our CEO. The patent application has a priority date of May 22, 2020.
Sunshine also eliminated their Class A Preferred shares:
Amendment to Articles of Incorporation eliminating Series “A” Preferred Shares and increasing the number of authorized Series “B” Preferred Shares (500,000).
They also filed an 8K and marked the following:
Emerging growth company [X]
And the following has always been checked (NOT a shell company)
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). [ ] Yes [X] No
The following is worth noting:
As of June 30, 2020 and December 31, 2019, the Company had $85,593 and $40,501 in cash on hand, respectively, and limited revenue-producing business and other sources of income. Additionally, as of June 30, 2020 and December 31, 2019, the outstanding liabilities of the Company totaled $665,780 and $833,527, respectively.
Plan of Operation
Despite the fact that we now are generating revenues, we have elected to include a Plan of Operation to discuss our ongoing research and development activities relating to our proprietary drug development operations, as well as, our other business activities.
News 
Market Data 
Discover 
